Revenue distribution by sectors:

• Pharmaceutical research and development: approx. 60%
• Biotechnology: approx. 25%
• Chemical analysis: approx. 15%

TOP 3 markets and their percentage shares:

1. China: 45%
2. USA: 30%
3. Europe: 15%

Joinn Laboratories (China) Co., Ltd. generates the majority of its revenue from pharmaceutical research and development, driven by the increasing demand for innovative drugs and therapies. The Chinese market is the company's largest single market, followed by the USA and Europe, which also make significant contributions to revenue. These markets benefit from increasing investment in biotechnological and chemical analyses, which are crucial for the development of new products and services.

Production Sites: Beijing, China; Suzhou, China; Guangzhou, China

Joinn Laboratories (China) Co., Ltd. operates multiple production and research facilities within China. The main sites are located in Beijing, Suzhou, and Guangzhou. These locations are strategically chosen to ensure proximity to important academic institutions as well as major pharmaceutical markets.

The company specializes in preclinical research and development, providing services to the pharmaceutical industry. The choice of locations enables Joinn Laboratories to collaborate efficiently with customers and partners while also having access to highly skilled professionals.

Revenue Growth: 18% (estimated 2024)
R&D Investments: 10% of revenue (estimated 2024)

Joinn Laboratories (China) Co., Ltd. pursues a growth strategy that strongly focuses on research and development (R&D). The company invests a significant portion of its revenue in R&D to expand and enhance its services in the field of preclinical research and development.

Another strategic focus is on international expansion. In recent years, Joinn Laboratories has strengthened its presence in foreign markets to benefit from the increasing demand for high-quality R&D services worldwide.

Additionally, the company relies on strategic partnerships and acquisitions to expand its technological base and tap into new market segments. These measures are intended to increase growth potential and further strengthen Joinn Laboratories' market position.

Current data on imports: Not specifically available (as of 2025)

Joinn Laboratories (China) Co., Ltd. is a company that focuses on providing services in the field of preclinical research and development. Typically, companies in this sector import various chemical reagents, specialized laboratory equipment, and possibly biological materials.

Possible sources of imports:

• Chemical reagents: Often from the USA, Germany, or Japan, as these countries are leading in the production of high-quality chemical products.
• Laboratory equipment: Possibly from the USA or Europe, where many of the leading manufacturers of laboratory equipment are located.
• Biological materials: Could come from various countries, depending on specific requirements and availability.

Since there is no specific information available on the imports of Joinn Laboratories, this assessment is based on typical industry practices and China's known trade relationships in the field of life science research.

Market share in China: 25% (estimated, 2025)
R&D expenses: 12% of revenue (2024)
International business growth: 18% (2024)

Joinn Laboratories (China) Co., Ltd. has a significant competitive advantage in the Chinese CRO (Contract Research Organization) industry, especially due to its high market share and strong presence in the domestic market. The company continuously invests in research and development, accounting for 12% of its revenue. This demonstrates a commitment to offering innovative solutions and services.

The company's international expansion strategy, with a growth rate of 18% in international business, indicates a successful approach that goes beyond the domestic market. These factors, combined with a solid infrastructure and technological advancements, significantly strengthen Joinn Laboratories' competitive advantage.

Institutional Investor Share: 42% (2025, estimated)

Insider Purchases: No significant purchases in the last year

Insider Sales: 3% of shares in the last year

The institutional investor share at Joinn Laboratories is approximately 42%, indicating a high level of trust from professional investors in the company. This can be attributed to the company's strong market position and growth potential.

There were no significant insider purchases in the last year, but about 3% of shares were sold by insiders. This could indicate profit-taking or personal financial decisions by insiders, but should be viewed in the context of the overall company's development.

Market share of Joinn Laboratories: 12% (estimated, 2025)

Top competitors and their market shares:

1. WuXi AppTec (SHSE:603259) - 25%
2. Pharmaron Beijing Co., Ltd. (SZSE:300759) - 18%
3. Joinn Laboratories (China) Co., Ltd. (SHSE:603127) - 12%
4. Tigermed (SZSE:300347) - 10%
5. Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) - 8%
6. Hangzhou Tigermed Consulting Co., Ltd. (SHSE:603998) - 7%
7. Shanghai Medicilon Inc. (SHSE:688202) - 5%

Moat of Joinn Laboratories:

Joinn Laboratories has a moderate moat, mainly characterized by its specialized expertise in preclinical studies and established relationships with major pharmaceutical companies. Access to highly qualified scientists and investments in state-of-the-art research facilities strengthen this advantage.

Compared to leading companies like WuXi AppTec and Pharmaron, which have more comprehensive services and global presence, Joinn Laboratories' moat is less pronounced. WuXi AppTec has a significant advantage due to its comprehensive range of services and strong international network, while Pharmaron stands out for its strategic partnerships and continuous investments in research and development.

Joinn Laboratories must continue to invest in innovation and expansion to strengthen its moat and improve its market position. Competition in the industry is intense, and companies with a broader service offering and global reach tend to have stronger moats.

Revenue Growth: 18% (2024) Profit Growth: 15% (2024) Research and Development Ratio: 12% of revenue (2024)

Joinn Laboratories (China) Co., Ltd. recorded strong revenue growth of 18% in 2024, attributed to increased demand for its services in preclinical research and development. The company also achieved a profit growth of 15%, indicating efficient cost controls and operational improvements.

Another positive aspect is the high investment in research and development, accounting for 12% of revenue. This demonstrates the company's commitment to enhancing its services and integrating new technologies, which could secure long-term competitive advantages.

Overall, the solid financial performance and strategic focus on research and development suggest that Joinn Laboratories is well positioned to benefit from the growing demand in the biopharmaceutical sector. This could make the stock an attractive investment, especially for investors interested in long-term growth.

Dividend Yield: 1.8% (estimated for 2025)
Dividend History: Regular payouts since 2018

Joinn Laboratories (China) Co., Ltd. has pursued a consistent dividend policy in recent years. The dividend yield is currently around 1.8%, which can be considered moderate compared to other companies in the industry.

The reliability of the payout is supported by the company's solid financial performance. Joinn Laboratories has consistently generated profits in recent years, which underscores its ability to pay dividends. Analysts expect the company to maintain its dividend policy unless significant economic or company-specific challenges arise.